Asceneuron

Asceneuron is a clinical-stage biotech company focusing on neurodegenerative disorders. It develops orally bioavailable therapeutics for debilitating such disorders as orphan tauopathies, Alzheimer’s, and Parkinson’s disease. The company aims to prevent disease progression in tauopathies and reverse cognitive impairment in dementia.